Tagged with R

rare diseases The country manager of a leading German chemical and pharmaceutical company sheds light on her company’s activities in the rare diseases segment and speaks about the multiple benefits of promoting home care and greater patient autonomy. You are known for your medicines against diseases that are often neglected, such as…

biosimilars Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the opportunities in Biosimilar markets as well as the potential impact the Samsung brand will bring to the pharmaceutical industry. As…

biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…

generics Carlos Leigh, executive president of Peru’s Asociación de Laboratorios Farmacéuticos Latinoamericanos (ALAFAL), discusses the advantages that LATAM companies have over big pharma players looking to enter the Peruvian market, and offers his predictions for the future of the sector for growth. Can you introduce yourself to our readers? I actively worked in…

investemnt The stability of Peru’s economy in recent years has provided amply opportunity for multinational pharmaceutical companies to invest in the country. Augusto Rey de la Cuba, executive director of ALAFARPE (Asociación Nacional de Laboratorios Faramcéuticos de Perú), discusses intellectual property issues and investing in research in the country. Can you…

clinical trials Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers? 2014 was the 55th anniversary of Ahngook’s foundation. I have worked for Ahngook most of my career, although I did…

R&D Lee Kyoung-Ryul has served as Chairman of SCL Healthcare Group since 2007. He discusses the diagnostic service providers’ extensive network in Korea as well as their ambitious plans to export their systems to China. What has been the most important long-term goal for you since you started? The most important…

biotech On February second, the Korean Ministry of Health and Welfare announced the start of a second round of financing to the biopharmaceutical industry, as part of the Global Pharmaceutical Industry Development Fund (GPIDF). A total of USD 123 million will be invested in Korean pharmaceutical and biotech companies for the…

pharmaceuticals With a wealth of experience in different countries around the world, Christophe Piganiol came to Korea as general manager of Zuellig Pharma in 2010. Today he discusses the importance of transparency in a volatile market and the introduction of new business models to satisfy customer demand. What were your impressions…

rheumatology President of the Algerian League Against Rheumatism and leading rheumatologist discusses the state of the education sector with relation to the training up of medical specialists and raises the fact that the quality of healthcare services is inconsistent across different regions. Can you introduce yourself, and introduce rheumatology, your heart activity?…

healthcare The co-president of a research group dedicated to Euro-Mediterranean health sector issues analyses commonalities across the North African region and calls for a coordinated response to shared challenges. He also delivers a comparative assessment of the Algerian market. What is your opinion about the evolution of the Algerian pharmaceutical industry and…

clinical research Clinical research and access are the name of the game. The Executive Director of the association bringing together the most important research-based pharmaceutical companies discusses how the association has stepped up to partner up with the government and stakeholders to fight for the same objective and create a better health…